Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-04-05 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the grant of share options and restricted share units under the company's 2022 Equity Incentive Plan. It details the number of options and restricted share units granted, the grantees including an executive director, exercise prices, vesting periods, and compliance with listing rules. The document is a regulatory announcement about equity compensation grants rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data, nor is it a proxy solicitation or remuneration report. The content fits the category of a regulatory announcement related to share-based compensation and equity incentive plans, which is best classified under Regulatory Filings (RNS) as it does not fit more specific categories like Director's Dealing or Share Issue/Capital Change (since it is about grants under an existing plan, not new share issuance announcements). The document length and detail confirm it is not a brief announcement or a report publication notice.
2024-04-05 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Annual Report Classification · 100% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023' and contains detailed consolidated financial statements including balance sheets, statements of operations, cash flows, and notes. It also includes an independent auditor's report with an opinion on the consolidated financial statements prepared under U.S. GAAP. The presence of comprehensive financial data, audit opinion, and detailed financial disclosures indicates this is a full annual report rather than a brief earnings release or announcement. The document length is substantial (15,000 characters), and it contains the full financial statements, not just an announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K).
2024-03-27 English
CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding a change in the use of proceeds from its Global Offering. It references the original prospectus and details the reallocation of funds previously designated for specific purposes. The document is relatively short (4602 characters) and does not contain financial statements or detailed financial data. It is an update on capital use and financing activities rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-03-27 English
Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 95% confidence The document is a letter dated March 21, 2024, from Zai Lab Limited addressed to non-registered shareholders. It informs shareholders about the company's adoption of electronic dissemination of corporate communications, including annual reports, interim reports, notices of general meetings, circulars, proxy forms, and listing documents. The letter provides instructions on how shareholders can receive printed copies if desired and includes a reply form for shareholders to request printed versions. There is no actual financial data, analysis, or detailed report content present. The document serves as a notification about the method of distribution of corporate communications rather than the communications themselves. It is also relatively short (8319 characters) and primarily informational. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about corporate communication dissemination and does not contain the actual reports or financial statements.
2024-03-21 English
Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 95% confidence The document is a letter dated March 21, 2024, from Zai Lab Limited to its registered shareholders regarding the arrangement for electronic dissemination of corporate communications. It explains the company's adoption of electronic delivery for documents such as annual reports, interim reports, notices of general meetings, circulars, proxy forms, and listing documents. The letter solicits shareholders to provide their email addresses to receive these communications electronically and offers options for receiving printed copies. There is no actual financial data, financial statements, or detailed report content included. The document is essentially an announcement about how future corporate communications will be distributed, not the report itself. It is also longer than 5,000 characters but does not contain substantive financial or operational data. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about corporate communication practices rather than a report or presentation.
2024-03-21 English
NOTICE OF BOARD ACTION
Report Publication Announcement Classification · 95% confidence The document is a short announcement (2518 characters) from Zai Lab Limited regarding the upcoming board meeting to approve and publish the annual results for the year ended December 31, 2023. It references that the annual results have already been announced and filed with the SEC as a Form 10-K. The announcement states that the results to be published under HK Listing Rules will be the same as those previously announced, with some additional HK-specific disclosures. The document does not contain the actual annual report or detailed financial data but is notifying the market of the board's planned approval and publication of the annual results. This fits the pattern of a Report Publication Announcement (RPA), which is a short notice about the timing and release of a report rather than the report itself. Therefore, the correct classification is RPA with high confidence.
2024-03-18 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.